Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Why Summit Therapeutics Stock Is Sinking Today


Shares of Summit Therapeutics (NASDAQ: SMMT) were sinking 22.6% as of 11:10 a.m. ET on Tuesday. This sell-off follows a similar steep decline of 22% on Friday after Summit revealed late-stage data for its lead candidate, ivonescimab, in combination with chemotherapy in treating non-small cell lung cancer (NSCLC).

In a regulatory filing on Friday, Summit referenced top-line data included in a presentation by its Chinese partner, Akeso, at the 2024 American Society of Clinical Oncology (ASCO) annual meeting. Patients receiving ivonescimab in combination with chemotherapy had a median progression-free survival of 7.06 months compared to 4.8 months for patients receiving only chemotherapy. However, 61.5% of patients receiving the combo experienced severe or medically significant treatment-emergent adverse events.

Investors reacted negatively to the late-stage data for ivonescimab. However, there was some good news: China's National Medical Products Administration gave the drug its first regulatory approval on Friday as a second-line treatment for patients with epidermal growth factor receptor (EFGR) mutated, advanced or metastatic NSCLC.

Continue reading


Source Fool.com

Summit Therapeutics plc Aktie

0,20 €
-33,45 %
Summit Therapeutics plc muss heute herbe Verluste wegstecken. Die Aktie notiert im Vergleich zu gestern um -33,45 % tiefer.

Like: 0
Teilen

Kommentare